𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-dose cytosine arabinoside in the treatment of refractory acute nonlymphocytic leukemia in adults: Results of two six-day regimens

✍ Scribed by Herzig, Roger H. ;Herzig, Geoffrey P. ;Lazarus, Hillard M. ;Wolff, Steven N. ;Phillips, Gordon L.

Publisher
John Wiley and Sons
Year
1982
Tongue
English
Weight
289 KB
Volume
10
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

High-dose cytosine arabinoside (Ara-C) was used in adult patients with refractory acute nonlymphoblastic leukemia, either alone (3 g/m2 every 12 h X 12 doses) or with 3 additional days of anthracycline antibiotics. The systemic toxicities were similar for both groups without an increase in the group receiving anthracyclines. Bone marrow recovery was also similar for these groups. The antileukemic effect was not statistically increased in the group receiving anthracyclines, but when a comparison of the complete remission late in resistant patients is made, there is a trend toward a greater number of complete remissions when anthracyclines are included in the regimen (p = 0.09). High-dose Ara-C is effective therapy for refractory leukemia; the addition of anthracyclines may enhance the effect of the Ara-C.

πŸ“œ SIMILAR VOLUMES

Treatment of acute nonlymphocytic leukem
Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside
✍ Letendre, Louis ;Niedringhaus, Robert D. ;Therneau, Terry M. ;Gastineau, Dennis πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 362 KB πŸ‘ 1 views

Effective treatment of the elderly patients (265 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (AM-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] I-hour infusion q12 hours

High antileukemic activity of sequential
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias : Results of a clinical Phase II study
✍ Wolfgang Kern; Eberhard Schleyer; Michael Unterhalt; Bernhard WΓΆrmann; Thomas BΓΌ πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 147 KB πŸ‘ 2 views

Department of Heremission whereas 5 patients (23%) succumbed to early death and 3 patients (14%) matology and Oncology, Go Β¨ttingen, Germany. did not respond. Blood counts recovered at a median of 33.5 days after the start 2 Westfa Β¨lische Wilhelms University, Department of treatment and complete r